Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31035574 | 0.84 | TTR (0.44) | TTRENPP2CA1CA2LPL | |
| SCHEMBL17236432 | 0.83 | TTR (0.52) | TTRENPP2CA1CA2LPL | |
| SCHEMBL29953894 | 0.82 | LPL (0.47) | TTRENPP2CA1CA2LPL | |
| SCHEMBL2413286 | 0.82 | LPL (0.47) | TTRENPP2CA1CA2LPL | |
| SCHEMBL3780619 | 0.80 | ENPP2 (0.48) | TTRENPP2CA1CA2LPL | |
| SCHEMBL16702930 | 0.77 | TTR (0.42) | TTRENPP2CA2 | |
| SCHEMBL16576629 | 0.77 | TTR (0.42) | TTRENPP2CA1CA2LPL | |
| SCHEMBL21501435 | 0.77 | ENPP2 (0.46) | TTRENPP2CA1CA2LPL | |
| SCHEMBL16898955 | 0.77 | KLF10 (0.47) | ENPP2CA1CA2TSHR | |
| SCHEMBL24012619 | 0.75 | ENPP2 (0.44) | TTRENPP2CA1CA2LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124304-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | TTR 3132/4885ENPP2 1210/4885CA1 2631/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | TTR 1533/4885ENPP2 2657/4885CA1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.